Cardiac sarcomere inhibitors

Patent metadata

Field	Value
Publication number	US-12286437-B2
Application number	US-202418423156-A
Country	US
Kind code	B2
Filing date	Jan 25, 2024
Priority date	Mar 4, 2021
Publication date	Apr 29, 2025
Grant date	Apr 29, 2025

Abstract

Provided are compounds of Formula (I):

or stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R 1 , R 2 , R 3 , and R 4 are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. Also provided are methods of using a compound of Formula (I), or stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

First claim

The invention claimed is:

1. A method of treating a heart disease in a subject in need thereof, comprising administering to the subject a compound of formula:

or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein the heart disease is hypertrophic cardiomyopathy.

3. The method of claim 2 , wherein the hypertrophic cardiomyopathy is obstructive or nonobstructive or is caused by (i) sarcomeric mutations, (ii) non-sarcomeric mutations, or (iii) both sarcomeric mutations and non-sarcomeric mutations.

4. The method of claim 1 , wherein the heart disease is heart failure with preserved ejection fraction.

5. The method of claim 1 , wherein the heart disease is selected from the group consisting of diastolic dysfunction, primary or secondary restrictive cardiomyopathy, myocardial infarction and angina pectoris, left ventricular outflow tract obstruction, hypertensive heart disease, congenital heart disease, cardiac ischemia, coronary heart disease, diabetic heart disease, congestive heart failure, right heart failure, cardiorenal syndrome, and infiltrative cardiomyopathy.

6. The method of claim 1 , wherein the heart disease is or is related to one or more conditions selected from the group consisting of cardiac senescence, diastolic dysfunction due to aging, left ventricular hypertrophy, and concentric left ventricular remodeling.

7. A method of treating a disease or condition associated with hypertrophic cardiomyopathy in a subject in need thereof, comprising administering to the subject a compound of formula:

or a pharmaceutically acceptable salt thereof.

8. The method of claim 7 , wherein the disease or condition is selected from the group consisting of Fabry's Disease, Danon Disease, mitochondrial cardiomyopathies, and Noonan Syndrome.

9. A method of treating a disease or condition that is associated with secondary left ventricular wall thickening in a subject in need thereof, comprising administering to the subject a compound of formula:

or a pharmaceutically acceptable salt thereof.

10. The method of claim 9 , wherein the disease or condition is selected from the group consisting of hypertension, valvular heart diseases, aortic stenosis, Mitral valve regurgitation, metabolic syndromes, diabetes, obesity, end stage renal disease, scleroderma, sleep apnea, amyloidosis, Fabry's disease, Friedreich Ataxia, Danon disease, Noonan syndrome, and Pompe disease.

11. A method of treating a disease or condition that is associated with small left ventricular cavity and cavity obliteration, hyperdynamic left ventricular contraction, myocardial ischemia, or cardiac fibrosis in a subject in need thereof, comprising administering to the subject a compound of formula:

or a pharmaceutically acceptable salt thereof.

12. A method of treating heart failure with preserved ejection fraction in a subject in need thereof, comprising administering to the subject a compound of formula:

13. A method of inhibiting a cardiac sarcomere, comprising contacting the cardiac sarcomere with a compound of formula:

or a pharmaceutically acceptable salt thereof.

14. The method of claim 3 , wherein the hypertrophic cardiomyopathy is caused by sarcomeric mutations.

15. The method of claim 14 , wherein the sarcomeric mutation is a mutation in myosin heavy chain β (MHC-β), cardiac muscle troponin T (cTnT), tropomyosin alpha-1 chain (TPM1), myosin-binding protein C cardiac-type (MYBPC3), cardiac troponin 1 (cTnI), myosin essential light chain (ELC), titin (TTN), myosin regulatory light chain 2 ventricular/cardiac muscle isoform (MLC-2), cardiac muscle alpha actin, or muscle LIM protein (MLP).

16. The method of claim 15 , wherein the sarcomeric mutation is a mutation in MHC-β.

17. The method of claim 15 , wherein the sarcomeric mutation is a mutation in cTnT.

18. The method of claim 15 , wherein the sarcomeric mutation is a mutation in MYBPC3.

19. The method of claim 3 , wherein the hypertrophic cardiomyopathy is caused by non-sarcomeric mutations.

20. The method of claim 19 , wherein the non-sarcomeric mutation is a mutation in protein kinase AMP-activated non-catalytic subunit gamma 2 (PRKAG2).

Assignees

• Cytokinetics Inc

Inventors

• Morgan Bradley P
• Chuang Chihyuan
• Ashcraft Luke W
• Ho Justin
• Garcia Alfredo
• Chandra Aroop

Classifications

• A61P9/04

  Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure · CPC title

• A61P21/00

  Drugs for disorders of the muscular or neuromuscular system · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61K31/499

  Spiro-condensed pyrazines or piperazines · CPC title

• A61K31/501

  not condensed and containing further heterocyclic rings · CPC title